Brief: Renovorx Announces New Positive Interim Late-Stage Data For Cancer Treatment
29/06/2023 13:16
June 29 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX ANNOUNCES NEW POSITIVE INTERIM PHASE III DATA
DEMONSTRATING RENOVOGEM™ DELAYS CANCER PROGRESSION BY EIGHT
MONTHS IN LOCALLY ADVANCED PANCREATIC CANCER
* RENOVORX- SIX-MONTH OVERALL SURVIVAL BENEFIT WITH
RENOVOGEM
VERSUS SYSTEMIC CHEMOTHERAPY; 65% REDUCTION IN ADVERSE EFFECTS
Source text for Eikon: ID:nBw4lDZ4ga
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies